VFC's Stock House: It's 'Now Time' For Amarin

(EstateNewsWire.com, July 20, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, highlighted on Friday the pending catalyst provided by next week's FDA approval decision for Amarin Corp (AMRN).

Amarin's high triglyceride drug, AMR-101, is widely-expected to receive approval, which would clear the way for the company to land a major partner or buyer.

Shares of Amarin Corp (AMRN) were setting new 52-week highs during early trading on Thursday as investors jumped in to take positions before next week's key date when the FDA is set to render a decision on the approval of AMR-101 for the treatment of high triglycerides. As noted earlier in the week, approval is all but assured - at least according to most investors and analysts who believe in the very strong Phase III data registered by AMR-101 - especially after a curious "gaffe" on Thursday morning, seemingly by Amarin itself, that sparked a rally and led to the setting of the new 52-week high.

A website advertising the "FDA approved" Vascepa drug - AMR-101 - briefly came on line on Thursday morning, hinting to investors that the company has already received notification from the FDA that the product was approved - even though no such formal announcement has been made. The site was quickly taken back off line and Amarin issued a statement regarding the incident via an 8k filing stating that the information on approval "was inadvertently published through a draft website that is under design by third parties on behalf of Amarin. The information was outdated and should not be relied upon as accurate. AMR101 review at FDA is still pending. No determinations have been made by FDA on its review of the AMR101 New Drug Application ("NDA")."

Regardless of what the company said about the incident, the rumor mill is swirling.

Theories are circulating that the company 'accidentally-on-purpose' wanted to give the investing community a heads up that approval was coming to drive the shorts out of the stock in order to allow the share price to run, while other theories believe that the intended run is to boost the value of the company in preparation for buyout offers.

Many also believe that this was a clear sign that Amarin already has a partnership in hand, pending the products approval, and the product is soon set to hit the open market following an official FDA announcement.

For full report visit: http://vfcsstockhouse.com/blog/article/-it-s-now-time-for-amarin-amrn-

For a full list of hot stocks to watch for the week visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-16-july-ko-jnj-goog-tlle-imsc-ssh-amrn-ttnp-actc-mric-vz-yum-amzn-appl-fb-cmcsa-yhoo-msft-rimm-gs-ms-bsx-si-sppi-pbth-mrk-vvus-ko-celh-ge-cpst-jpm-wfc-bac-c-ubs-rbs-db-usb-

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

About VFCsStockHouse.com:

VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, growth stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.

For full disclaimer visit: http://vfcsstockhouse.com

VFC's Stock House

VFC

240-786-2111

vfc@vfcsstockhouse.com

Source: EmailWire.Com